Novo Nordisk Weight Loss Drug Fails Trial
Novo Nordisk announced a drug trial failure on Monday. The company's weight loss drug did not meet its main goal.
The drug achieved only 23% weight loss. This was lower than existing treatments.
Patients receive the drug as a once-a-week injection. Novo Nordisk's stock fell 15% on Monday.
The company is based in Copenhagen, Denmark. Denmark's stock market fell alongside Novo Nordisk's decline.
Klear Note — Novo Nordisk makes popular weight loss drugs used by millions worldwide. When big companies' stock prices fall sharply, it affects entire stock markets.
Key Terms 1
- Novo Nordisk Danish company that makes obesity and weight loss drugs